Hyderabad, India · Full time · Posted Nov 21, 2026
Let’s build the future of medicine—together.
YOUR ROLE
As a Scientist in In Vivo Pharmacology at Enveda, you will establish and validate in vivo disease models and evaluate how our small molecule candidates behave in living systems. Reporting to the Principal Scientist, Biology, you will design and run PK, PD and efficacy studies from early exploration through to IND, investigate mechanisms of action, and help test novel therapeutic hypotheses that shape where our programmes go next.
WHAT YOU'LL DO
Execute in vivo pharmacology studies to evaluate small molecule candidates, investigate mechanisms of action, and explore novel therapeutic hypotheses
Contribute to the design, planning and execution of pharmacokinetic, pharmacodynamic and efficacy studies from early exploratory work through to IND stage
Perform standard rodent procedures including plasma and serum collection, IP/IV dosing, survival surgery, necropsy and tissue collection in line with approved protocols
Record experimental data and observations accurately and on time in company-specified formats
Contribute to study protocols, SOPs and methods, and participate in cross-functional team activities with creative ideas that advance projects
WHAT WE'RE LOOKING FOR
M.Pharm with 5-7 years, or PhD with 0-2 years, of experience in the drug discovery industry
Proficient in standard in vivo techniques: animal handling, blood collection, multi-route dosing, rodent survival surgery, necropsy and tissue dissection
Familiar with animal ethics and regulatory compliance requirements
Self-motivated and proactive, able to work independently and communicate clearly in English
Strong work ethic, scientific curiosity, and a can-do, will-do attitude
We hire for trajectory, not just credentials. If you meet most of the above and care deeply about this problem, we want to hear from you.
ABOUT ENVEDA
We're a clinical-stage, AI-enabled biotech discovering medicines four times faster than the industry standard.
We recently raised $150M in a Series D, reached unicorn status, and advanced our first drug into Phase 2 trials. Forbes named us one of America's Best Startup Employers. Newsweek recognized us as a Top 100 Most Loved Workplace.
We're building something rare and we're just getting started.
Ovii Interpretation
This Scientist, In Vivo Pharmacology role evaluates small-molecule drug candidates in living systems. You will develop and run disease-model, pharmacokinetic, pharmacodynamic, and efficacy studies, contributing evidence for therapeutic programs from early exploration through IND.
Role at a glance
In vivo pharmacologyDrug discoveryRodent disease modelsPK/PD and efficacy studiesSmall-molecule candidatesIND-stage research
Skills mentioned
In vivo pharmacologyAnimal handlingBlood collectionMulti-route dosingIntraperitoneal (IP) dosingIntravenous (IV) dosingRodent survival surgeryNecropsyTissue dissectioncollection
What you will likely work on
Establish and validate in vivo disease models for drug-discovery programs.
Run studies assessing small-molecule candidates and investigate their mechanisms of action.
Contribute to the design, planning, and execution of PK, PD, and efficacy studies through IND stage.
Perform rodent procedures, including blood collection, dosing, survival surgery, necropsy, and tissue collection, under approved protocols.
Document experimental observations and results accurately and on schedule.
Help develop study protocols, SOPs, and methods, and contribute ideas in cross-functional project work.
Good fit signals
Has drug-discovery industry experience through either an M.Pharm pathway or a PhD pathway, with the stated experience range for that pathway.
Can competently perform standard rodent handling, sampling, dosing, surgery, and tissue procedures.
Understands animal ethics and regulatory compliance requirements.
Works proactively and independently, communicates clearly in English, and brings scientific curiosity to experimental work.
Meet Enveda
Enveda is a clinical-stage biotechnology company developing small-molecule medicines by combining artificial intelligence, metabolomics, mass spectrometry and automated laboratory workflows with chemistry found in living organisms. Its PRISM platform analyzes large-scale chemical data to identify previously unexplored molecules and connect them with biological activity, enabling Enveda to select and develop drug candidates. The company has advanced multiple oral medicines into clinical development, including programs for inflammatory and metabolic diseases. Enveda operates major research and development facilities in Boulder, Colorado and Hyderabad, India, combining computational drug discovery, chemistry, biology and clinical development within one organization.
Founded
2019
Company size
201-500 employees
Company stage
Not known
Headquarters
Boulder, USA
Why work here
Enveda combines software, AI, mass spectrometry, laboratory automation and clinical drug development, giving candidates opportunities to work across unusually interdisciplinary technical and scientific problems. The company raised a $311 million Series E in 2026, bringing total capital raised to more than $845 million, and has advanced multiple oral medicines into human trials with positive early clinical readouts. Current engineering roles use technologies including Python, FastAPI, Vue 3, TypeScript, Databricks, Prefect and Azure. Enveda's careers materials list flexible PTO, a company-wide year-end break, 12 weeks of paid parental leave and a work-from-home stipend. Many laboratory and scientific roles are on-site in Boulder or Hyderabad, reflecting the hands-on nature of its research.
Founder and CEO of Enveda. Colluru previously served as the first Innovation Scientist and Product Manager at Recursion, where he also established its Portfolio/Early Commercial team. He earned a PhD in immuno-oncology and cellular and molecular biology at the University of Wisconsin-Madison and has more than a decade of experience in translational biomedical discovery.
Scientific Co-Founder of Enveda and a professor at UC San Diego. Dorrestein specializes in mass spectrometry, metabolomics, natural-product chemistry and molecular networking. He earned a PhD in Chemical Biology from Cornell University and has developed widely used approaches for analyzing the chemical diversity of biological systems.
AAAugust AllenChief Technology OfficerView bioHide bio
Chief Technology Officer overseeing Enveda's technology platform for identifying the structure and function of molecules from nature. Allen previously worked at Recursion, where he helped scale its high-content imaging platform, and joined Enveda in 2021. His work spans laboratory automation, software and high-throughput biotechnology.
HGHannah GordonChief Scientific OfficerView bioHide bio
Chief Scientific Officer responsible for scientific strategy and translational drug discovery. Gordon has more than a decade of biotechnology experience, including at Recursion. She holds a PhD in Human Genetics and an MS in Clinical Investigation from the University of Utah, with expertise spanning translational biology and technology-enabled drug discovery.
NRNiranjan RaoChief Development OfficerView bioHide bio
Chief Development Officer overseeing advancement of Enveda's programs through clinical development. Rao previously held senior development roles at Asana BioSciences, Endo Pharmaceuticals, Kyowa Hakko Kirin, Forest Laboratories and Aventis. He is a clinical pharmacologist and a Fellow of the American College of Clinical Pharmacology.
JKJason KimChief Financial OfficerView bioHide bio
Chief Financial Officer responsible for Enveda's financial strategy, operations and growth. Kim previously served as President, COO and CFO of Molecular Templates and held roles at ImClone Systems, OSI Pharmaceuticals, Domain Associates and Safeguard Scientifics. He earned an MBA from Wharton and a BA in Neuroscience from Wesleyan University.
IKInhwan KimChief Strategy OfficerView bioHide bio
Chief Strategy Officer helping shape Enveda's pipeline, portfolio strategy and long-term company direction. Kim previously managed portfolio strategy at BridgeBio and worked at McKinsey advising biotechnology, pharmaceutical and public-health organizations. He holds a PharmD from Rutgers University and an MBA from Northwestern University's Kellogg School of Management.
RBRobert BuckleyChief People OfficerView bioHide bio
Chief People Officer leading Enveda's people and talent organization. Buckley previously served as Chief People Officer at RainFocus and held HR leadership roles at Thumbtack, eBay and GE Healthcare. His experience includes building and scaling global workforces across technology and healthcare organizations.
Enveda Collaborates with Anthropic to Accelerate Drug Development
Enveda·
Enveda reported using Anthropic's Claude models in AI-assisted workflows for pharmaceutical manufacturing and regulatory documentation, including batch-record review and preparation of regulatory content while retaining expert oversight and quality controls.
Enveda Raises $311 Million From Leading AI and Biotech Investors
Enveda·
Enveda closed a $311 million Series E led by Catalio Capital Management, bringing total capital raised since inception to more than $845 million. The funding is intended to advance its clinical pipeline and expand its PRISM discovery platform and automated laboratory.
Enveda Reports Positive Phase 1 Results for ENV-308
Enveda·
Enveda reported Phase 1 results for ENV-308, an investigational oral medicine inspired by the exercise-associated metabolite Lac-Phe. The study enrolled 88 healthy volunteers, and the company outlined plans for additional trials related to metabolic health and weight maintenance.
Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial
Enveda·
Enveda announced positive Phase 1b results for ENV-294, its investigational once-daily oral therapy for moderate-to-severe atopic dermatitis, providing early clinical validation for a medicine discovered through its chemistry-first platform.